| Title: | The effect of baseline prediabetes on the relation between lipoprotein (a) and incident type 2 diabetes mellitus and cardiovascular outcomes: observations from the UK-Biobank. |
| Journal: | Diabetes & Metabolic Syndrome Clinical Research & Reviews |
| Published: | 25 Apr 2026 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/42055523/ |
| DOI: | https://doi.org/10.1016/j.dsx.2026.103422 |
Publication 17846
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
AIMS: To explore the effect of prevalent prediabetes (preDM) on relation between lipoprotein (a) Lp(a) and incident diabetes mellitus (T2DM) and cardiovascular outcomes.</p>
METHOD: Subjects without diabetes with available Lp(a) in UK-Biobank database, were divided into Group 1 (HbA1c <5.7%, (39 mmol/mol)), Group 2 (HbA1c 5.7-<6.0% (39-<42 mmol/mol)) and Group 3 (HbA1c ≥ 6.0% (42 mmol/mol)). Incident T2DM and major adverse cardiovascular event (MACE) (death, non-fatal myocardial infarction, ischaemic stroke, or coronary revascularisation) during follow up was identified. The unadjusted and adjusted risk of T2DM and MACE between Lp(a) quartiles was estimated in the 3 groups.</p>
RESULTS: 11.9 years follow up; 3.3% subjects developed T2DM. Lp(a) Q2-4 had 7-11% lower risk of T2DM compared to Q1. Adjusted risk of T2DM was lower in Q3 (HR 0.88, 0.80-0.98, p = 0.017) and Q4 (HR 0.82, 0.74-0.91, p < 0.001) only in Group 3. MACE was higher in Q3 and Q4 in whole cohort and Group 1(Q3: HR 1.04, 1.01-1.08, p = 0.025; Q4: HR 1.16, 1.11-1.20, p < 0.0001) but only in Q4 (HR 1.14, 1.07-1.23, p = 0.0002) in Group 2. MACE was similar between quartiles in Group 3.</p>
CONCLUSION: Lp(a) is inversely related to T2DM risk only in subjects with severe prediabetes. Direct association between Lp(a) and cardiovascular outcomes is seen only in subjects without prediabetes.</p>
3 Authors
- Sudipta Chattopadhyay
- Jason Sangha
- Thozhukat Sathyapalan
1 Application
| Application ID | Title |
|---|---|
| 64253 | In silico clinicogenomic risk prediction in atrial fibrillation and flutter: electrifying patient and clinician decision making |
Enabling scientific discoveries that improve human health